New Targeted Therapies Show Promise in Cancer

(MedPage Today) — A majority of patients with advanced EGFR/HER2-mutant non-small cell lung cancer (NSCLC) benefited from treatment with the tyrosine kinase inhibitor (TKI) poziotinib, according to a preliminary clinical trial.
An efficacy cohort…
Read More

Leave a Reply

%d bloggers like this: